Published : 29 May 2025
We are glad to announce that Aagami has been appointed by a new client who are “Metastasis Specialists” uncoupling Metastasis and Proliferation with their translational platform, machine learning, and known molecules to disrupt cancer treatment.
Aagami has received a mandate to help the client out-license their lead assets and platform. Asset MSAP031 stops Metastasis and is entering Phase 2 clinical trial.
The platform has also identified novel assets which is in early stage.
The client is funded by multiple renowned venture capitalists and angel investors and has also been the recipient of multiple grants.
Unique approach of client (uncoupling of proliferation and metastasis biology with translational significance) would excite Biopharma companies about the following:
a) Using their platform to find novel targets
b) Using platform to position small molecule pipeline (currently built as a second or third line of treatment) as a first line of treatment in an adjuvant setting.
c) Exploit our client expertise for their cancer of choice, identifying novel first-in-class targets
If you would like to know more, please contact us and we can send you a non-confidential presentation for your review.